Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.

CONCLUSION: The addition of everolimus to exemestane markedly prolonged PFS in patients with HR(+) advanced BC with disease recurrence/progression following prior NSAIs. These results further support the use of everolimus plus exemestane in this patient population. ClinicalTrials.gov #NCT00863655.
PMID: 24158787 [PubMed - as supplied by publisher]

Source: Advances in Therapy - October 25, 2013 Category: Drugs & Pharmacology Authors: Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS Tags: Adv Ther Source Type: research